Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma (NCT05108428)

🧪 Interventions in This Study

• Capecitabine (DRUG)
• FOLFOX regimen (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Moffitt Cancer Center — Tampa, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Rectal Adenocarcinoma

• ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer — Portland, Oregon
• ctDNA-Informed Management of Early-Stage Rectal Cancer — Sacramento, California
• Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors — Hartford, Connecticut
• Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer — Houston, Texas
• Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer — Portland, Oregon

Explore by condition: All Rectal Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.